Study S003217

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07533175
Acronym: AMAZE 2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 630
Start: 2026-04-13
Primary completion: 2028-08-07
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus; Overweight; Obesity
Interventions: DRUG:NNC0487-0111; DRUG:Placebo (matched to NNC0487-0111)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1313-6325; OTHER:2024-520441-23

Registered primary outcomes

Relative change in body weight [From baseline (week 0) to (week 84)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.